Definium Therapeutics (NASDAQ:DFTX) Shares Down 7.9% - Here's What Happened

Key Points

• Definium Therapeutics shares fell 7.9% to about $41.38, with trading volume down 84% from the average session. The stock’s decline came despite a consensus “Buy” rating and average analyst price target of $63.
• The company’s latest quarterly results disappointed investors: it reported a loss of $1.44 per share, missing the $0.55-per-share consensus estimate. Analysts expect a full-year loss of approximately $3.02 per share.
• Recent analyst opinions remain largely positive, including JonesTrading’s $90 price target, while insiders sold 48,096 shares worth roughly $2.17 million over the past 90 days.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report)'s stock price dropped 7.9% on Monday . The company traded as low as $41.25 and last traded at $41.38. Approximately 364,029 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 2,269,607 shares. The stock had previously closed at $44.91.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DFTX. Oppenheimer reaffirmed an "outperform" rating and issued a $70.00 price target on shares of Definium Therapeutics in a research note on Wednesday, August 12th. JonesTrading upped their price target on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Definium Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group set a $64.00 target price on Definium Therapeutics and gave the stock a "buy" rating in a research report on Thursday, August 13th. Finally, Maxim Group set a $55.00 target price on shares of Definium Therapeutics and gave the company a "buy" rating in a research note on Friday, August 14th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of "Buy" and an average price target of $63.00.

Definium Therapeutics Stock Performance

The stock has a 50 day moving average of $42.02 and a 200 day moving average of $27.88. The company has a market capitalization of $5.87 billion, a price-to-earnings ratio of -12.73 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, analysts predict that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, CFO Brandi Roberts sold 3,013 shares of the firm's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company's stock, valued at $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,096 shares of company stock valued at $2,165,763 in the last ninety days. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after buying an additional 2,003 shares in the last quarter. Nykredit A S bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $45,000. BNP Paribas Financial Markets raised its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock worth $55,000 after acquiring an additional 3,020 shares during the period. Caxton Associates LLP bought a new position in shares of Definium Therapeutics in the 3rd quarter valued at about $126,000. Finally, Mercer Global Advisors Inc. ADV boosted its position in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock valued at $259,000 after acquiring an additional 2,079 shares during the period. Institutional investors own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source